Development of recombinant hemoglobin-based oxygen carriers

Antioxidants and Redox Signaling

Volumn 18, Issue 17, 2013, Pages 2314-2328

  Varnado, Cornelius L ^a   Mollan, Todd L ^b   Birukou, Ivan ^c   Smith, Bryan J Z ^d   Henderson, Douglas P ^d   Olson, John S ^a  

^a RICE UNIVERSITY   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS OF THE PERMIAN BASIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMIN; IRON; NITRIC OXIDE; OXYGEN; RECOMBINANT HEMOGLOBIN;

AUTOOXIDATION; CHEMICAL MODIFICATION; DENATURATION; DISSOCIATION; ERYTHROCYTE; ESCHERICHIA COLI; GOOD MANUFACTURING PRACTICE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PURIFICATION; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD SUBSTITUTES; HEME; HEMOGLOBINS; HUMANS; NITRIC OXIDE; OXIDATION-REDUCTION; OXYGEN; PROTEIN BINDING; PROTEIN STABILITY; RECOMBINANT PROTEINS;

ESCHERICHIA COLI;

EID: 84876927609     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4917     Document Type: Review

References (164)

1. Abolghasemi H, Radfar MH, Tabatabaee M, Hosseini-Divkolayee NS, and Burkle FM, Jr. Revisiting blood transfusion preparedness: experience from the Bam earthquake response. Prehosp Disaster Med 23: 391-394, 2008.
2. Adachi K, Konitzer P, Lai CH, Kim J, and Surrey S. Oxygen binding and other physical properties of human hemoglobin made in yeast. Protein Eng 5: 807-810, 1992. (Pubitemid 23036552)
3. Alayash AI. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Nat Biotechnol 17: 545-549, 1999. (Pubitemid 29262916)
4. Alayash AI. Oxygen therapeutics: can we tame haemoglobin? Nat Rev Drug Discov 3: 152-159, 2004. (Pubitemid 38239776)
5. Alayash AI. Setbacks in blood substitutes research and development: a biochemical perspective. Clin Lab Med 30: 381-389, 2010.
6. Alayash AI. Haptoglobin: Old protein with new functions. Clin Chim Acta 412: 493-498, 2011.
7. Amin M, Fergusson D, Aziz A, Wilson K, Coyle D, and Hebert P. The cost of allogeneic red blood cells-A systematic review. Transfus Med 13: 275-285, 2003. (Pubitemid 37462040)
8. Baldwin AL. Blood substitutes and redox responses in themicrocirculation. Antioxid Redox Signal 6: 1019-1030, 2004. (Pubitemid 39434938)
9. Baldwin AL, Wiley EB, and Alayash AI. Comparison of effects of two hemoglobin-based O(2) carriers on intestinal integrity and microvascular leakage. Am J Physiol Heart Circ Physiol 283: H1292-H1301, 2002.
10. Baldwin AL, Wiley EB, and Alayash AI. Differential effects of sodium selenite in reducing tissue damage caused by three hemoglobin-based oxygen carriers. J Appl Physiol 96: 893-903, 2004. (Pubitemid 38248660)
11. Basha J, Dewitt R, Cable D, and Jones G. Transfusions and their costs: managing patients needs and hospitals economics. Internet J Emerg Intensive Care Med 9: 2006.
12. Behringer RR, Ryan TM, Reilly MP, Asakura T, Palmiter RD, Brinster RL, and Townes TM. Synthesis of functional human hemoglobin in transgenic mice. Science 245: 971-973, 1989. (Pubitemid 19224826)
13. Birukou I, Maillett DH, Birukova A, and Olson JS. Modulating distal cavities in the alpha and beta subunits of human HbA reveals the primary ligand migration pathway. Biochemistry 50: 7361-7374, 2011.
14. Birukou I, Schweers RL, and Olson JS. Distal histidine stabilizes bound O2 and acts as a gate for ligand entry in both subunits of adult human hemoglobin. J Biol Chem 285: 8840-8854, 2010.
15. Birukou I, Soman J, and Olson JS. Blocking the gate to ligand entry in human hemoglobin. J Biol Chem 286: 10515-10529, 2011.
16. Bratbak G and Dundas I. Bacterial dry matter content and biomass estimations. Appl EnvironMicrobiol 48: 755-757, 1984. (Pubitemid 14010843)
17. Brooks JP. Reengineering transfusion and cellular therapy processes hospitalwide: ensuring the safe utilization of blood products. Transfusion 45: 159S-171S, 2005.
18. Buehler PW and Alayash AI. All hemoglobin-based oxygen carriers are not created equally. Biochim Biophys Acta 1784: 1378-1381, 2008.
19. Buehler PW, D'Agnillo F, and Schaer DJ. Hemoglobinbased oxygen carriers: from mechanisms of toxicity and clearance to rational drug design. Trends Mol Med 16: 447-457, 2010.
20. Buehler PW, Karnaukhova E, Gelderman MP, and Alayash AI. Blood aging, safety, and transfusion: capturing the "radical" menace. Antioxid Redox Signal 14: 1713-1728, 2011.
21. Bunn HF, Esham WT, and Bull RW. The renal handling of hemoglobin. I. Glomerular filtration. J Exp Med 129: 909-923, 1969.
22. Bunn HF and Forget BG. Hemoglobin, Molecular, Genetic and Clinical Aspects. Philadelphia: Saunders, 1986.
23. Busch MP, Kleinman SH, and Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 289: 959-962, 2003. (Pubitemid 37432916)
24. Chamberland ME. Emerging infectious agents: do they pose a risk to the safety of transfused blood and blood products? Clin Infect Dis 34: 797-805, 2002. (Pubitemid 34194851)
25. Chamberland ME, Alter HJ, Busch MP, Nemo G, and Ricketts M. Emerging infectious disease issues in blood safety. Emerg Infect Dis 7: 552-553, 2001. (Pubitemid 32726845)
26. Chang TM. Future generations of red blood cell substitutes. J Intern Med 253: 527-535, 2003. (Pubitemid 36543292)
27. Cinat ME, Wallace WC, Nastanski F, West J, Sloan S, Ocariz J, and Wilson SE. Improved survival following massive transfusion in patients who have undergone trauma. Arch Surg 134: 964-968; discussion 968-970, 1999.
28. Coghlan D, Jones G, Denton KA, Wilson MT, Chan B, Harris R, Woodrow JR, and Ogden JE. Structural and functional characterisation of recombinant human haemoglobin A expressed in Saccharomyces cerevisiae. Eur J Biochem 207: 931-936, 1992.
29. Como JJ, Dutton RP, Scalea TM, Edelman BB, and Hess JR. Blood transfusion rates in the care of acute trauma. Transfusion 44: 809-813, 2004. (Pubitemid 38738407)
30. Cyranoski D. Tainted transfusion leaves Japan scrambling for safer blood tests. Nat Med 10: 217, 2004. (Pubitemid 38667600)
31. Dieryck W, Pagnier J, Poyart C, Marden MC, Gruber V, Bournat P, Baudino S, and Merot B. Human haemoglobin from transgenic tobacco. Nature 386: 29-30, 1997.
32. Dodd RY and Leiby DA. Emerging infectious threats to the blood supply. Annu Rev Med 55: 191-207, 2004. (Pubitemid 38316723)
33. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olson JS, and Lemon DD. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 16: 672-676, 1998. (Pubitemid 28334327)
34. Dong J, Olano JP, McBride JW, and Walker DH. Emerging pathogens: challenges and successes of molecular diagnostics. J Mol Diagn 10: 185-197, 2008. (Pubitemid 351692160)
35. Dou Y, Maillett DH, Eich RF, and Olson JS. Myoglobin as a model system for designing heme protein based blood substitutes. Biophys Chem 98: 127-148, 2002. (Pubitemid 34785987)
36. Doyle MP, Armstrong AM, Brucker EA, Fattor TJ, and Lemon DD. Design of second generation recombinant hemoglobin: minimizing nitric oxide scavenging and vasoactivity while maintaining efficacy. Artif Cells Blood Sub Immobil Biotech 29: 100, 2001.
37. Eder AF and Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med 131: 708-718, 2007. (Pubitemid 46726132)
38. Eich RF, Li T, Lemon DD, Doherty DH, Curry SR, Aitken JF, Mathews AJ, Johnson KA, Smith RD, Phillips GN, Jr., and Olson JS. Mechanism of NO-induced oxidation of myoglobin and hemoglobin. Biochemistry 35: 6976-6983, 1996. (Pubitemid 26182085)
39. Esquerra RM, Lopez-Pena I, Tipgunlakant P, Birukou I, Nguyen RL, Soman J, Olson JS, Kliger DS, and Goldbeck RA. Kinetic spectroscopy of heme hydration and ligand binding in myoglobin and isolated hemoglobin chains: an optical window into heme pocket water dynamics. Phys Chem Chem Phys 12: 10270-10278, 2010.
40. Estep T, Bucci E, Farmer M, Greenburg G, Harrington J, Kim HW, Klein H, Mitchell P, Nemo G, Olsen K, Palmer A, Valeri CR, and Winslow R. Basic science focus on blood substitutes: a summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop, March 1, 2006. Transfusion 48: 776-782, 2008. (Pubitemid 351430350)
41. Faggiano S, Bruno S, Ronda L, Pizzonia P, Pioselli B, and Mozzarelli A. Modulation of expression and polymerization of hemoglobin polytaur, a potential blood substitute. Arch Biochem Biophys 505: 42-47, 2011.
42. Feng L, Gell DA, Zhou S, Gu L, Kong Y, Li J, Hu M, Yan N, Lee C, Rich AM, Armstrong RS, Lay PA, Gow AJ, Weiss MJ, Mackay JP, and Shi Y. Molecular mechanism of AHSPmediated stabilization of alpha-hemoglobin. Cell 119: 629-640, 2004. (Pubitemid 39535751)
43. Feng L, Zhou S, Gu L, Gell DA, Mackay JP, Weiss MJ, Gow AJ, and Shi Y. Structure of oxidized alpha-haemoglobin bound to AHSP reveals a protective mechanism for haem. Nature 435: 697-701, 2005. (Pubitemid 40825516)
44. Ferguson E, Prowse C, Townsend E, Spence A, Hilten JA, and Lowe K. Acceptability of blood and blood substitutes. J Intern Med 263: 244-255, 2008. (Pubitemid 351207348)
45. Foley EW. Physiologically relevant reactions of myoglobin and hemoglobin with NO [Ph.D. Thesis]. Rice University, Houston, TX, 2006, http://hdl.handle. net/1911/18903.
46. Fronticelli C and Koehler RC. Design of recombinant hemoglobins for use in transfusion fluids. Crit Care Clin 25: 357-371, Table of Contents, 2009.
47. Fronticelli C, O'Donnell JK, and Brinigar WS. Recombinant human hemoglobin: expression and refolding of betaglobin from Escherichia coli. J Protein Chem 10: 495-501, 1991.
48. Gell D, Kong Y, Eaton SA, Weiss MJ, and Mackay JP. Biophysical characterization of the alpha-globin binding protein alpha-hemoglobin stabilizing protein. J Biol Chem 277: 40602-40609, 2002.
49. Gibson QH, Regan R, Olson JS, Carver TE, Dixon B, Pohajdak B, Sharma PK, and Vinogradov SN. Kinetics of ligand binding to Pseudoterranova decipiens and Ascaris suum hemoglobins and to Leu-29/Tyr sperm whale myoglobin mutant. J Biol Chem 268: 16993-16998, 1993. (Pubitemid 23236924)
50. Glynn SA, Busch MP, Schreiber GB, Murphy EL, Wright DJ, Tu Y, and Kleinman SH. Effect of a national disaster on blood supply and safety: the September 11 experience. JAMA 289: 2246-2253, 2003. (Pubitemid 37430193)
51. Goodnough LT, Brecher ME, Kanter MH, and AuBuchon JP. Transfusion medicine. First of two parts-blood transfusion. N Engl J Med 340: 438-447, 1999. (Pubitemid 29084776)
52. Graves PE, Henderson DP, Horstman MJ, Solomon BJ, and Olson JS. Enhancing stability and expression of recombinant human hemoglobin in E. coli: progress in the development of a recombinant HBOC source. Biochim Biophys Acta 1784: 1471-1479, 2008.
53. Greinacher A, Fendrich K, Alpen U, and Hoffmann W. Impact of demographic changes on the blood supply: Mecklenburg-West Pomerania as a model region for Europe. Transfusion 47: 395-401, 2007.
54. Hartman JC, Argoudelis G, Doherty D, Lemon D, and Gorczynski R. Reduced nitric oxide reactivity of a new recombinant human hemoglobin attenuates gastric dysmotility. Eur J Pharmacol 363: 175-178, 1998. (Pubitemid 29057765)
55. Henkel-Honke T and Oleck M. Artificial oxygen carriers: a current review. AANA J 75: 205-211, 2007. (Pubitemid 46906371)
56. Hermann J, Corso C, and Messmer KF. Resuscitation with recombinant hemoglobin rHb2.0 in a rodent model of hemorrhagic shock. Anesthesiology 107: 273-280, 2007. (Pubitemid 47196491)
57. Hernan RA, Hui HL, Andracki ME, Noble RW, Sligar SG, Walder JA, and Walder RY. Human hemoglobin expression in Escherichia coli: importance of optimal codon usage. Biochemistry 31: 8619-8628, 1992.
58. Hernan RA and Sligar SG. Tetrameric hemoglobin expressed in Escherichia coli. Evidence of heterogeneous subunit assembly. J Biol Chem 270: 26257-26264, 1995.
59. Hess J and Thomas M. Blood use in war and disaster: lessons from the past century, Transfusion 43: 1622-1633, 2003. (Pubitemid 37371835)
60. Hess JR. Blood use in war and disaster: The U.S. experience. Scand J Trauma Resusc Emerg Med 13: 74-81, 2005.
61. Hirayama C and Sakata M. Chromatographic removal of endotoxin from protein solutions by polymer particles. J Chromatogr B Analyt Technol Biomed Life Sci 781: 419-432, 2002. (Pubitemid 35351680)
62. Hoffman SJ, Looker DL, Roehrich JM, Cozart PE, Durfee SL, Tedesco JL, and Stetler GL. Expression of fully functional tetrameric human hemoglobin in Escherichia coli. Proc Natl Acad Sci USA 87: 8521-8525, 1990.
63. Huang H and Olsen KW. Thermal stabilities of hemoglobins crosslinked with different length reagents. Artif Cells Blood Substit Immobil Biotechnol 22: 719-724, 1994. (Pubitemid 24252423)
64. Intaglietta M. Editorial: Blood Substitutes Better Than Blood. Transfus Altern Tranfus Med 9: 199-203, 2008.
65. Jia Y, Ramasamy S, Wood F, Alayash AI, and Rifkind JM. Cross-linking with O-raffinose lowers oxygen affinity and stabilizes haemoglobin in a non-cooperative T-state conformation. Biochem J 384: 367-375, 2004. (Pubitemid 39656249)
66. Kaca W, Roth RI, and Levin J. Hemoglobin, a newly recognized lipopolysaccharide (LPS)-binding protein that enhances LPS biological activity. J Biol Chem 269: 25078-25084, 1994. (Pubitemid 24311778)
67. Kato GJ and Taylor JG. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol 148: 690-701, 2010.
68. Kihm AJ, Kong Y, Hong W, Russell JE, Rouda S, Adachi K, Simon MC, Blobel GA, and Weiss MJ. An abundant erythroid protein that stabilizes free alpha-haemoglobin. Nature 417: 758-763, 2002. (Pubitemid 34640631)
69. Kim-Shapiro DB, Schechter AN, and Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 26: 697-705, 2006. (Pubitemid 43732141)
70. Klein H. Will blood transfusion ever be safe enough? JAMA 284: 238-240, 2000. (Pubitemid 30460870)
71. Klein H. How safe is blood, really? Adv Transfus Safety 38: 1-104, 2010.
72. Kluger R. Red cell substitutes from hemoglobin-do we start all over again? Curr Opin Chem Biol 14: 538-543, 2010.
73. Korz DJ, Rinas U, Hellmuth K, Sanders EA, and Deckwer WD. Simple fed-batch technique for high cell density cultivation of Escherichia coli. J Biotechnol 39: 59-65, 1995.
74. Kresie L. Artificial blood: an update on current red cell and platelet substitutes. Proc (Bayl Univ Med Cent) 14: 158-161, 2001.
75. Kumar R. Recombinant hemoglobins as blood substitutes: a biotechnology perspective. Proc Soc Exp Biol Med 208: 150-158, 1995.
76. Lemon DD, Boland EJ, Nair PK, Olson JS, and Hellums JD. Effects of physiological factors on oxygen transport in an in vitro capillary system. Adv Exp Med Biol 222: 37-44, 1988.
77. Lloyd E and Mauk AG. Formation of sulphmyoglobin during expression of horse heart myoglobin in Escherichia coli. FEBS Lett 340: 281-286, 1994. (Pubitemid 24080966)
78. Logan JS and Martin MJ. Transgenic swine as a recombinant production system for human hemoglobin. Methods Enzymol 231: 435-445, 1994.
79. Looker D, Abbott-Brown D, Cozart P, Durfee S, Hoffman S, Mathews AJ, Miller-Roehrich J, Shoemaker S, Trimble S, Fermi G, et al. A human recombinant haemoglobin designed for use as a blood substitute. Nature 356: 258-260, 1992.
80. Looker D, Mathews AJ, Neway JO, and Stetler GL. Expression of recombinant human hemoglobin in Escherichia coli. Methods Enzymol 231: 364-374, 1994.
81. Lowe K. Blood substitutes: from chemistry to clinic. J Mat Chem 16: 4189-4196, 2006. (Pubitemid 44658462)
82. Luban NL. Transfusion safety: where are we today? Ann N Y Acad Sci 1054: 325-341, 2005. (Pubitemid 43031040)
83. Maillett DH, Simplaceanu V, Shen TJ, Ho NT, Olson JS, and Ho C. Interfacial and distal-heme pocket mutations exhibit additive effects on the structure and function of hemoglobin. Biochemistry 47: 10551-10563, 2008.
84. Malhotra AK, Kelly ME, Miller PR, Hartman JC, Fabian TC, and Proctor KG. Resuscitation with a novel hemoglobinbased oxygen carrier in a Swine model of uncontrolled perioperative hemorrhage. J Trauma 54: 915-924, 2003. (Pubitemid 36758802)
85. Manjula BN, Kumar R, Sun DP, Ho NT, Ho C, Rao JM, Malavalli A, and Acharya AS. Correct assembly of human normal adult hemoglobin when expressed in transgenic swine: chemical, conformational and functional equivalence with the human-derived protein. Protein Eng 11: 583-588, 1998. (Pubitemid 28362672)
86. Mollan TL. The role of the alpha hemoglobin stabilizing protein in human hemoglobin assembly [Ph.D. Thesis]. Rice University, Houston TX, 2011, https://scholarship.rice .edu/handle/1911/68348.
87. Moore E. Blood substitutes: the future is now. J Am Coll Surg 196: 1-17, 2003. (Pubitemid 36070989)
88. Moore E. Emerging role of hemoglobin solutions in trauma care. Transfus Altern Tranfus Med 6: 69-77, 2005.
89. Mujeeb SA and Jaffery SH. Emergency blood transfusion services after the 2005 earthquake in Pakistan. Emerg Med J 24: 22-24, 2007. (Pubitemid 46099304)
90. Nagai K, Perutz MF, and Poyart C. Oxygen binding properties of human mutant hemoglobins synthesized in Escherichia coli. Proc Natl Acad Sci USA 82: 7252-7255, 1985. (Pubitemid 16193719)
91. Nagai K and Thogersen HC. Generation of beta-globin by sequence-specific proteolysis of a hybrid protein produced in Escherichia coli. Nature 309: 810-812, 1984. (Pubitemid 14119436)
92. Nagai K and Thogersen HC. Synthesis and sequencespecific proteolysis of hybrid proteins produced in Escherichia coli. Methods Enzymol 153: 461-481, 1987.
93. Nair PK, Huang NS, Hellums JD, and Olson JS. A simple model for prediction of oxygen transport rates by flowing blood in large capillaries. Microvasc Res 39: 203-211, 1990. (Pubitemid 20154445)
94. Ness PM and Cushing MM. Oxygen therapeutics: pursuit of an alternative to the donor red blood cell. Arch Pathol Lab Med 131: 734-741, 2007. (Pubitemid 46726134)
95. O'Donnell JK, Martin MJ, Logan JS, and Kumar R. Production of human hemoglobin in transgenic swine: an approach to a blood substitute. Cancer Detect Prev 17: 307-312, 1993.
96. Ogden JE, Coghlan D, Jones G, Denton KA, Harris R, Chan B, Woodrow J, and Wilson MT. Expression and assembly of functional human hemoglobin in S. cerevisiae. Biomater Artif Cells Immobilization Biotechnol 20: 473-475, 1992.
97. Ogden JE, Harris R, and Wilson MT. Production of recombinant human hemoglobin A in Saccharomyces cerevisiae. Methods Enzymol 231: 374-390, 1994.
98. Olson JS, Eich RF, Smith LP, Warren JJ, and Knowles BC. Protein engineering strategies for designing more stable hemoglobin-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 25: 227-241, 1997. (Pubitemid 27165754)
99. Olson JS, Foley EW, Rogge C, Tsai AL, Doyle MP, and Lemon DD. No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 36: 685-697, 2004. (Pubitemid 38264413)
100. Olson JS and Maillett DH. Designing Recombinant Hemoglobin for Use as a Blood Substitute. London, United Kingdom: Elsevier, 2005.
101. Olson JS, Soman J, and Phillips GN, Jr. Ligand pathways in myoglobin: a review of Trp cavity mutations. Iubmb Life 59: 552-562, 2007. (Pubitemid 47265857)
102. Otsubo H and Yamaguchi K. Current risks in blood transfusion in Japan. Jpn J Infect Dis 61: 427-433, 2008.
103. Page TC, Light WR, McKay CB, and Hellums JD. Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance. Microvasc Res 55: 54-64, 1998. (Pubitemid 28368413)
104. Pape A and Habler O. Alternatives to allogeneic blood transfusions. Best Pract Res Clin Anaesthesiol 21: 221-239, 2007. (Pubitemid 46888189)
105. Pape A, Stein P, Horn O, and Habler O. Clinical evidence of blood transfusion effectiveness. Blood Transfus 7: 250-258, 2009.
106. Petsch D and Anspach FB. Endotoxin removal from protein solutions. J Biotechnol 76: 97-119, 2000.
107. Piro MC, Militello V, Leone M, Gryczynski Z, Smith SV, Brinigar WS, Cupane A, Friedman FK, and Fronticelli C. Heme pocket disorder in myoglobin: reversal by acidinduced soft refolding. Biochemistry 40: 11841-11850, 2001. (Pubitemid 32906045)
108. Plomer J, Ryland J, Mathews A, Traylor D, Milne E, Durfee S, et al. Purification of hemoglobins U.S. Patent 5,840,851 (PCT publication number WO 96/15151), 1997.
109. Raat NJ. Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock. J Lab Clin Med 146: 304-305, 2005. (Pubitemid 41464408)
110. Raat NJH, Liu J-F, Doyle MP, Burhop KE, Klein J, and Ince C. Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock. J Lab Clin Med 145: 21-32, 2005. (Pubitemid 40139074)
111. Reeder BJ. The redox activity of hemoglobins: from physiologic functions to pathologic mechanisms. Antioxid Redox Signal 13: 1087-1123, 2010.
112. Reeder BJ, Grey M, Silaghi-Dumitrescu RL, Svistunenko DA, Bulow L, Cooper CE, and Wilson MT. Tyrosine residues as redox cofactors in human hemoglobin: implications for engineering nontoxic blood substitutes. J Biol Chem 283: 30780-30787, 2008.
113. Reeder BJ, Svistunenko DA, Cooper CE, and Wilson MT. Engineering tyrosine-based electron flow pathways in proteins: the case of aplysia myoglobin. J Am Chem Soc 134: 7741-7749, 2012.
114. Reeder BJ and Wilson MT. Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease States. Curr Med Chem 12: 2741-2751, 2005. (Pubitemid 41601571)
115. Resta TC, Walker BR, Eichinger MR, and Doyle MP. Rate of NO scavenging alters effects of recombinant hemoglobin solutions on pulmonary vasoreactivity. J Appl Physiol 93: 1327-1336, 2002.
116. Richard-Fogal CL, Frawley ER, Feissner RE, and Kranz RG. Heme concentration dependence and metalloporphyrin inhibition of the system I and II cytochrome c assembly pathways. J Bacteriol 189: 455-463, 2007. (Pubitemid 46106378)
117. Rinas U, Hellmuth K, Kang R, Seeger A, and Schlieker H. Entry of Escherichia coli into stationary phase is indicated by endogenous and exogenous accumulation of nucleobases. Appl Environ Microbiol 61: 4147-4151, 1995.
118. Roback JD, Combs MR, Grossman BJ, and Hillyer CD. AABB Technical Manual, 16th ed, www.aabb.org/Pages/Homepage.aspx, 2008.
119. Roth RI. Hemoglobin enhances the binding of bacterial endotoxin to human endothelial cells. Thromb Haemost 76: 258-262, 1996. (Pubitemid 26285262)
120. Roth RI, Kaca W, and Levin J. Hemoglobin: a newly recognized binding protein for bacterial endotoxins (LPS). Prog Clin Biol Res 388: 161-172, 1994.
121. Rother RP, Bell L, Hillmen P, and Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin. JAMA 293: 1653-1662, 2005. (Pubitemid 40471796)
122. Ryan TM, Townes TM, Reilly MP, Asakura T, Palmiter RD, Brinster RL, and Behringer RR. Human sickle hemoglobin in transgenic mice. Science 247: 566-568, 1990.
123. Sanders KE, Ackers G, and Sligar S. Engineering and design of blood substitutes. Curr Opin Struct Biol 6: 534-540, 1996. (Pubitemid 26315849)
124. Sanna MT, Razynska A, Karavitis M, Koley AP, Friedman FK, Russu IM, Brinigar WS, and Fronticelli C. Assembly of human hemoglobin. Studies with Escherichia coli-expressed alpha-globin. J Biol Chem 272: 3478-3486, 1997.
125. Savitsky JP, Doczi J, Black J, and Arnold JD. A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther 23: 73-80, 1978. (Pubitemid 8290413)
126. Schaer DJ and Alayash AI. Clearance and control mechanisms of hemoglobin from cradle to grave. Antioxid Redox Signal 12: 181-184, 2010.
127. Schmidt PJ. Blood and disaster-supply and demand. N Engl J Med 346: 617-620, 2002.
128. Schmunis GA and Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev 18: 12-29, 2005. (Pubitemid 40170659)
129. Schreiber GB, Sanchez AM, Glynn SA, and Wright DJ. Increasing blood availability by changing donation patterns. Transfusion 43: 591-597, 2003. (Pubitemid 36506354)
130. Scott EE, Gibson QH, and Olson JS. Mapping the pathways for O2 entry into and exit from myoglobin. J Biol Chem 276: 5177-5188, 2001.
131. Scott EE, Paster EV, and Olson JS. The stabilities of mammalian apomyoglobins vary over a 600-fold range and can be enhanced by comparative mutagenesis. J Biol Chem 275: 27129-27136, 2000.
132. Seghatchian J and de Sousa G. An overview of unresolved inherent problems associated with red cell transfusion and potential use of artificial oxygen carriers and ECO-RBC: current status/future trends. Transfus Apher Sci 37: 251-259, 2007. (Pubitemid 350181795)
133. Shander A, Hofmann A, Gombotz H, Theusinger OM, and Spahn DR. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 21: 271-289, 2007. (Pubitemid 46893970)
134. Sharma A, Martin MJ, Okabe JF, Truglio RA, Dhanjal NK, Logan JS, and Kumar R. An isologous porcine promoter permits high level expression of human hemoglobin in transgenic swine. Biotechnology (N Y) 12: 55-59, 1994.
135. Shen TJ, Ho NT, Simplaceanu V, Zou M, Green BN, Tam MF, and Ho C. Production of unmodified human adult hemoglobin in Escherichia coli. Proc Natl Acad Sci USA 90: 8108-8112, 1993. (Pubitemid 23260864)
136. Shen TJ, Ho NT, Zou M, Sun DP, Cottam PF, Simplaceanu V, Tam MF, Bell DA, Jr., and Ho C. Production of human normal adult and fetal hemoglobins in Escherichia coli. Protein Eng 10: 1085-1097, 1997. (Pubitemid 28004656)
137. Silverman TA and Weiskopf RB. Hemoglobin-based oxygen carriers: current status and future directions. Transfusion 49: 2495-2515, 2009.
138. Smith BJZ, Gutierrez P, Guerrero E, Brewer CJ, and Henderson DP. Development of a method to produce hemoglobin in a bioreactor culture of Escherichia coli BL21(DE3) transformed with a plasmid containing Plesiomonas shigelloides heme transport genes and modified human hemoglobin genes. Appl Environ Microbiol 77: 6703-6705, 2011.
139. Smith L. The effects of amino acid substitution on apomyoglobin stability, folding intermediates, and holoprotein expression. In: Biochemistry & Cell Biology [Ph.D. Thesis]. Houston, TX: Rice University, 2003.
140. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci 39: 75-82, 2008.
141. Spahn DR and Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des 11: 4099-4114, 2005.
142. Stowell CP. What happened to blood substitutes? Transfus Clin Biol 12: 374-379, 2005. (Pubitemid 41802973)
143. Sullivan MT, Cotten R, Read EJ, and Wallace EL. Blood collection and transfusion in the United States in 2001. Transfusion 47: 385-394, 2007.
144. Swanson ME, Martin MJ, O'Donnell JK, Hoover K, Lago W, Huntress V, Parsons CT, Pinkert CA, Pilder S, and Logan JS. Production of functional human hemoglobin in transgenic swine. Biotechnology (N Y) 10: 557-559, 1992.
145. Tame J, Shih DT, Pagnier J, Fermi G, and Nagai K. Functional role of the distal valine (E11) residue of alpha subunits in human haemoglobin. J Mol Biol 218: 761-767, 1991. (Pubitemid 121003373)
146. Tappenden J. Artificial blood substitutes. J R Army Med Corps 153: 3-9, 2007.
147. Tsuruga M, Matsuoka A, Hachimori A, Sugawara Y, and Shikama K. The molecular mechanism of autoxidation for human oxyhemoglobin. Tilting of the distal histidine causes nonequivalent oxidation in the beta chain. J Biol Chem 273: 8607-8615, 1998. (Pubitemid 28176135)
148. Vallelian F, Pimenova T, Pereira CP, Abraham B, Mikolajczyk MG, Schoedon G, Zenobi R, Alayash AI, Buehler PW, and Schaer DJ. The reaction of hydrogen peroxide with hemoglobin induces extensive alpha-globin crosslinking and impairs the interaction of hemoglobin with endogenous scavenger pathways. Free Radic Biol Med 45: 1150-1158, 2008.
149. Vandegriff KD and Olson JS. Morphological and physiological factors affecting oxygen uptake and release by red blood cells. J Biol Chem 259: 12619-12627, 1984. (Pubitemid 15203773)
150. Varnado CL and Goodwin DC. System for the expression of recombinant hemoproteins in Escherichia coli. Protein Expr Purif 35: 76-83, 2004. (Pubitemid 38497909)
151. Vasseur-Godbillon C, Hamdane D, Marden MC, and Baudin-Creuza V. High-yield expression in Escherichia coli of soluble human alpha-hemoglobin complexed with its molecular chaperone. Protein Eng Des Sel 19: 91-97, 2006.
152. Villarreal DM, Phillips CL, Kelley AM, Villarreal S, Villaloboz A, Hernandez P, Olson JS, and Henderson DP. Enhancement of recombinant hemoglobin production in Escherichia coli BL21(DE3) containing the Plesiomonas shigelloides heme transport system. Appl Environ Microbiol 74: 5854-5856, 2008.
153. Vincent JL, Sakr Y, De Backer D, and Van der Linden P. Efficacy of allogeneic red blood cell transfusions. Best Pract Res Clin Anaesthesiol 21: 209-219, 2007. (Pubitemid 46888186)
154. von Dobschuetz E, Hutter J, Hoffmann T, and Messmer K. Recombinant human hemoglobin with reduced nitric oxide-scavenging capacity restores effectively pancreatic microcirculatory disorders in hemorrhagic shock. Anesthesiology 100: 1484-1490, 2004. (Pubitemid 38679318)
155. Wagenbach M, O'Rourke K, Vitez L, Wieczorek A, Hoffman S, Durfee S, Tedesco J, and Stetler G. Synthesis of wild type and mutant human hemoglobins in Saccharomyces cerevisiae. Biotechnology (N Y) 9: 57-61, 1991.
156. Weickert MJ, Pagratis M, Curry SR, and Blackmore R. Stabilization of apoglobin by low temperature increases yield of soluble recombinant hemoglobin in Escherichia coli. Appl Environ Microbiol 63: 4313-4320, 1997. (Pubitemid 27485756)
157. Weickert MJ, Pagratis M, Glascock CB, and Blackmore R. A mutation that improves soluble recombinant hemoglobin accumulation in Escherichia coli in heme excess. Appl Environ Microbiol 65: 640-647, 1999. (Pubitemid 29075109)
158. Whitaker B, Henry R, Green J, Schlumpf K, and Schreiber G. The 2009 National Blood Collection and Utilization Survey. Washington, DC: U.S. Department of Health and Human Services, 2009.
159. Whitaker TL. Residues controlling the functions and stability of the CD corner in myoglobin and hemoglobin [Ph.D. Thesis]. Rice University, Houston, TX, 1995, http://hdl.handle.net/1911/16913.
160. Winslow RM (ed.) Blood Substitutes, 1st ed. Oxford, United Kingdom: Academic Press, 2006.
161. World Health Organization. WHO Global Database on Blood Safety and Blood Safety Indicators, www.who.int/blood safety/global-database/, 2007.
162. Yasuda J, Ichikawa T, Tsuruga M, Matsuoka A, Sugawara Y, and Shikama K. The alpha 1 beta 1 contact of human hemoglobin plays a key role in stabilizing the bound dioxygen. Eur J Biochem 269: 202-211, 2002.
163. Yu X, Kong Y, Dore LC, Abdulmalik O, Katein AM, Zhou S, Choi JK, Gell D, Mackay JP, Gow AJ, and Weiss MJ. An erythroid chaperone that facilitates folding of alpha-globin subunits for hemoglobin synthesis. J Clin Invest 117: 1856-1865, 2007. (Pubitemid 47036319)
164. Zou S, Musavi F, Notari EP 4th, and Fang CT. Changing age distribution of the blood donor population in the United States. Transfusion 48: 251-257, 2008.